2/26/2007 Salt Lake City, UT press release PRNewswire (www.prnewswire.com) BSD Medical Corp. today reviewed the presentations made at the annual conference of the American College of Radiation Oncology (ACRO) held February 22-24 in San Diego. The emphasis was on the clinical science behind hyperthermia therapy for treating cancer and BSD Medical's advanced systems used to deliver the therapy. In addition to a 45-minute lecture by Dr. Mark Hurwitz of Harvard Medical School on the results of clinical studies on hyperthermia and the technological capabilities now emerging to deliver the cancer therapy, a commercial exhibit by BSD Medical also showcased the science supporting the therapy and the advanced features of the BSD's cancer therapy systems. The Science The lecture included a review of Phase III clinical studies that have been conducted adding hyperthermia to radiation treatments as compared to radiation treatments alone. * In a clinical study conducted in Italy involving 41 patients (44 nodes) with inoperable Stage IV head and neck cancer, patients receiving hyperthermia and radiation therapy had an 83% complete response rate compared to 41% for patients who received radiation therapy alone, and the 3-year local relapse-free survival rate was 24% for patients receiving only radiation and 68% for those who received both radiation and hyperthermia therapy. (See International Journal of Radiation Oncology, Biology, Physics Vol. 28, pp. 163-169.) * In an international clinical study conducted in Denmark, the Netherlands and Norway involving 128 patients with recurrent or metastatic malignant melanoma, patients who received hyperthermia therapy along with [...]

2/26/2007 Staten Island, NY Diane O'Donnell Staten Island Advance (www.silive.com) TomoTherapy combines daily CT scans to check for any changes in size or location of a tumor with the ability to target it with high doses of radiation while decreasing damage to the surrounding healthy tissues and organs Paul Lewek takes off his Mets baseball cap and settles his lanky 6-foot-5 frame onto a movable table connected to a large donut-shaped machine. For the 57-year-old retired cop, this is day 11 of his 6 1/2 week Monday to Friday regimen of TomoTherapy, a relatively new approach to treating cancerous tumors. After having his right tonsil and a golf ball-size mass removed from his neck in December to battle advanced tonsillar cancer, Lewek shruggingly accepts the routine. Lewek is the first head-and-neck cancer patient to be treated with the more than $3 million, state-of-the-art machine at TomoTherapy of Staten Island, housed in West Brighton-based Regional Radiology. The TomoTherapy Hi-Art System machine, which debuted on the Island last month, is one of only two in the New York City area and 71 nationwide. According to Patty Kitowski, marketing communications manager of Madison, Wis.-based TomoTherapy Incorporated, which created the machine, there are 102 units worldwide. TomoTherapy combines daily CT scans to check for any changes in size or location of a tumor with the ability to accurately target it with high doses of radiation while sparing healthy surrounding tissue to a greater degree than was previously possible. The process is achieved through Image [...]

2/26/2007 Monza, Italy Werner Garavello et al. Oral Oncol, February 15, 2007 Previous studies on squamous cell carcinoma of the tongue have reported conflicting results with respect to age and prognosis. The aim of this study is to elucidate if any differences in outcome exist between patients younger and older than 40 years. A case-control study was performed. Patients recorded in the head and neck cancer registry of Milano-Bicocca School of Medicine between January 1981 and December 1998 were reviewed. Cases were patients with squamous cell carcinoma of the tongue aged 40 years or less. Controls were patients older than 40 who were matched to cases for diagnosis, sex and TNM classification. Two controls were matched for each case, thus forty-six cases and 92 controls were selected. The frequency of recurrences was found to be significantly higher in younger patients. The survival analysis further supports this conclusion (log-rank test, p=0.002). The number of cancer-related deaths in patients younger and older than 40 years were 23 (50%) and 31 (34%), respectively (p=0.10). A statistical significant difference emerged when the number of deaths was compared using survival curves (log-rank test, p=0.05). In conclusion, in patients with squamous cell carcinoma of the tongue, young age is an independent predictor of worse survival. Authors: Werner Garavello, Roberto Spreafico, and Renato Maria Gaini Authors' affiliation: Department of Otorhinolaryngology, Head and Neck Surgery, University of Milano-Bicocca, DNTB, Ospedale San Gerardo, 20052 Monza (MI), Italy.

2/26/2007 Boston, MA staff Medical Matrix (www.hemonctoday.com) An analysis of nicotine yield from major brand-name cigarettes sold in Massachusetts between 1997 and 2005 has confirmed that manufacturers have steadily increased the levels of this agent in cigarettes. The analysis, based on data submitted to the Massachusetts Department of Public Health by the manufacturers, found that increases in smoke nicotine yield per cigarette average 1.6% each year, or about 11% through a seven-year period. A research team from the Tobacco Control Research Program at the Harvard School of Public Health performed the data analysis. “Cigarettes are finely-tuned drug delivery devices, designed to perpetuate a tobacco pandemic,” Howard Koh, MD, associate dean for public health practice at the Harvard School of Public Health said in a press release. “Yet precise information about these products remains shrouded in secrecy, hidden from the public. Policy actions today requiring the tobacco industry to disclose critical information about nicotine and product design could protect the next generation from the tragedy of addiction.” In addition to the increase in yield, the researchers concluded that manufacturers accomplished the increase not only by intensifying the concentration of nicotine in the tobacco but also by modifying several design features of cigarettes to increase the number of puffs per cigarette. The end result is a product that is potentially more addictive. The researchers also examined all market categories and found that smoke nicotine yields were increased in the cigarettes of each of the four major manufacturers and across all the major [...]

2/26/2007 Chapel Hill, NC ES Oh and DM Laskin J Oral Maxillofac Surg, March 1, 2007; 65(3): 424-6 Purpose: Early detection of oral cancer is crucial in improving survival rate. To improve early detection, the use of a dilute acetic acid rinse and observation under a chemiluminescent light (ViziLite; Zila Pharmaceuticals, Phoenix, AZ) has been recommended. However, to date, the contributions of the individual components of the system have not been studied. The present study was done to investigate the efficacy of the individual components of the ViziLite system in providing improved visualization of early oral mucosal lesions. Patients and Methods: A total of 100 patients, 39 males and 61 females, age 18 to 93 years (mean age, 44 years), who presented to the Virginia Commonwealth University School of Dentistry for dental screening were examined. There were 58 Caucasians, 29 African-Americans, 5 Hispanics, 6 Asians, and 2 of mixed ethnicity. Thirty-five patients smoked, 53 used alcohol, and 25 both smoked and drank. After written consent, the oral cavity was examined under incandescent light for soft tissue abnormalities. After 1-minute rinse with 1% acetic acid, the mouth was re-examined for additional mucosal abnormalities. Then, the mouth was examined once again using the ViziLite system's chemiluminescent light. Any lesions detected by these 3 examinations that were clinically undiagnosable were brush biopsied (Oral CDx) for determination of cellular representation. Results: In the original examination of the 100 patients, 57 clinically diagnosable benign lesions (eg, linea alba, leukoedema) and 29 clinically undiagnosable lesions were [...]

2/26/2007 Barcelona, Spain press release PRNewswire (www.prnewswire.com) GlaxoSmithKline (GSK) today announced the start of an international Phase III trial of its investigational cancer treatment TYKERB(lapatinib) in squamous cell carcinoma of the head and neck (SCCHN). This announcement coincided with the International Meeting on Innovative Approaches in Head & Neck Oncology, Barcelona, Spain, February 22-24 supported by the European Society for Therapeutic Radiology and Oncology (ESTRO), where GSK presented results from a Phase I study of lapatinib in SCCHN. Lapatinib is an investigational drug that is not yet approved for marketing by any regulatory body. This large adjuvant trial will compare the effectiveness of oral lapatinib versus placebo given in high-risk patients following surgery. SCCHN is the sixth most common cancer worldwide (1): 600,000 people are diagnosed with SCCHN annually (1), 40,000 in the United States (2) and 100,800 in Europe alone.(3) 40,000 people die from the disease every year.(3) The design of this Phase III trial was based on recent results from two large-scale, independent randomized studies which have established the addition of chemotherapy to radiation therapy as the new standard of care in the post-operative treatment of high-risk SCCHN patients with additional use of chemotherapy.(4, 5) However, research suggests that approximately one quarter to one third of advanced head and neck cancers that are primarily treated with surgery and radiation therapy come back following treatment.(4, 5) "The initiation of this trial represents another exciting step towards understanding the role of lapatinib in other tumor types beyond breast cancer," says [...]

2/26/2007 Atlanta, GA staff Atlanta Journal-Constitution (ajc.com) Slowly but surely, American kids have gotten the message that cigarette smoking is stinky, smelly and a hazard to your health. Now, if only they would believe the same about cigars. While cigarette consumption declined in the United States by 10 percent from 2000 to 2004, cigar consumption jumped 28 percent, according to a recent report published in the American Journal of Public Health. Other studies have found that teens who smoke cigars are definitely behind some of that increase. For instance, a 2004 survey conducted in Cleveland found that 23 percent of the 4,409 teens polled preferred cigars, compared to 16 percent choosing cigarettes. And the increase may not yet have peaked, said John Banzhaf, executive director of Action on Smoking and Health, a national legal action anti-smoking organization based in Washington, D.C. "Many of the factors that began leading to the [cigar] increase are still present," Banzhaf said. They include the perception that cigars look fashionable and the fact that high-profile politicians and others are seen smoking them regularly, he said. "We have Arnold (Schwarzenegger, California's governor), smoking cigars and occasionally, Bill Clinton," he said. "More and more women are smoking cigars." But it's not just politicians and women who are fueling the image that cigars are hip, said Scott Goold, director of Tobacco Freedom, an Albuquerque, N.M.-based group. "Our popular culture is filled with images of cigars," he said. Your neighbor passes them out, for instance, when the family has [...]

2/25/2007 London, England Katherine Griffiths Telegraph.co.uk GlaxoSmithkline will start an advanced trial of its experimental breast cancer drug to test its efficacy against tumours in the head and neck. GSK has filed Tykerb for approval with America's Food and Drug Administration and European regulators as a breast cancer drug. A decision by the FDA is expected on March 13 and in Europe in September. Analysts and doctors believe it will experience the same levels of demand as Herceptin, which is now widely available on the NHS after patients sued their local primary care trusts to get access to the drug. As well as looking highly effective against certain forms of breast cancer, Tykerb has shown early signs of combating other forms of cancer, such as brain tumours. Analysts believe Tykerb will fall into the category of blockbuster drugs, with sales of more than £500m. GSK, headed by chief executive Jean-Pierre Garnier, announced last night it would start a Phase III trial in patients who have just had surgery, giving them the drug in the hope it will stop another tumour from growing. GSK presented data at a medical meeting in Barcelona at the end of last week from a Phase I study. The drug taken jointly with chemotherapy and radiotherapy had a positive response in 89pc of patients. Paolo Paoletti, vice president of GSK's Oncology Development Centre, said: "Having already shown such promise as a breast cancer treatment, we are excited to continue investigating lapatinib [Tykerb]. "We think it may [...]

2/25/2007 London, UK staff This London (www.thisislondon.co.uk) Cancer patients are having to wait months beyond recommended dates for treatment to prevent the disease returning, say frustrated consultants. After tumours are removed by surgery, patients should get follow-up radiotherapy within 28 days, according to Royal College of Radiologists guidelines. But in many areas the wait is much longer. In Kent, for instance, the waiting time for breast cancer patients is at least three months. Three patients have seen the disease return during the long gap between operation and radiotherapy. Peter Jones, consultant surgeon in Maidstone, says: 'We believe that it's totally unacceptable.' Explaining why he is going public with news of the situation on tomorrow night's Channel 4 Dispatches programme, NHS: Where Did All The Money Go?, he says: 'We have been left with no alternative but to bring this to the attention of the media.' He is backed by Dr David Dodwell at Cookridge Hospital in Leeds, who says: 'Delayed radiotherapy for a range of cancers increases the risk of local recurrence and other problems. That's in head and neck cancers and sarcomas, cervix cancer and lung cancer, as well as breast cancer.' Five UK radiotherapy units have an average wait of 28 days, which means many patients are waiting longer. In two centres, more than three-quarters of patients are missing the 28-day window. But although the Department of Health has set targets for initial cancer treatment, there is none set for post-operative therapy. Shadow Health Minister Mike Penning said: [...]

2/25/2007 Toronto, Ontario, Canada Paul Taylor Globe and Mail (www.theglobeandmail.com) Construction workers have double the risk of the general population of developing head, neck and esophageal cancers, according to a landmark study by Canadian researchers. "They work in dusty environments and are exposed to all kinds of hazardous substances," said lead researcher James Brophy, executive director of the Occupational Health Clinics for Ontario Workers. "We actually know from other studies that workers -- particularly construction workers -- are bearing an elevated risk for a whole range of cancers." The new study, based on data gathered through the Windsor Regional Cancer Centre, is one of the first to focus on head, neck and esophageal cancers. It is being published todayin the International Journal of Occupational and Environmental Health. Head and neck cancers primarily involve the upper respiratory passages, such as the nose, mouth and throat. The esophagus is the hollow, muscular tube that carries food and liquids from the throat to the stomach. Among other potentially harmful chemicals, those in the construction trades can come into contact with asbestos and silica -- two well-known carcinogens -- when working in older buildings. Dr. Brophy, who holds an academic post at the University of Windsor, said very little research is now being done to measure the link between different jobs and cancer risks. That means "there is no way to identify potential populations at risk and to do something to try to prevent these exposures."